These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20524323)

  • 1. Use of bortezomib for prevention and treatment of rejection in sensitized patients.
    Hartono C; Lubetzky M; Aull MJ; Saal S; Figueiro J; Kapur S; Dadhania D
    Clin Transpl; 2009; ():499-503. PubMed ID: 20524323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases.
    Cooper JE; Wiseman AC; Chan L
    Clin Transpl; 2009; ():455-9. PubMed ID: 20524314
    [No Abstract]   [Full Text] [Related]  

  • 3. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
    Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Tevar A; Woodle ES
    Transplantation; 2008 Dec; 86(12):1754-61. PubMed ID: 19104417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
    Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
    Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib rescue in refractory acute humoral rejection--report of a case.
    Shapiro R; Basu A; Zeevi A; Lunz J; Mapara M; Randhawa P; Morgan C; Tan HP; Sharma V
    Clin Transpl; 2009; ():431-2. PubMed ID: 20524310
    [No Abstract]   [Full Text] [Related]  

  • 6. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.
    Pavlakis M
    Clin Transpl; 2009; ():343-5. PubMed ID: 20524296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
    Stuckey LJ; Kamoun M; Chan KM
    Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
    Hardinger KL; Murillo D
    Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.
    Al Meshari K
    Clin Transpl; 2009; ():385-6. PubMed ID: 20524302
    [No Abstract]   [Full Text] [Related]  

  • 10. Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases.
    Mai HL; Cesbron A; Brouard S; Blanchol G; Cantarovich D; Dantal J; Hourmant M; Lino M; Meurette A; Gosselin M; Abbadie O; Soulillou JP; Giral M
    Clin Transpl; 2009; ():361-8. PubMed ID: 20524299
    [No Abstract]   [Full Text] [Related]  

  • 11. A summary of bortezomib use in transplantation across 29 centers.
    Everly MJ
    Clin Transpl; 2009; ():323-37. PubMed ID: 20524294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination of post-transplant donor-specific HLA antibodies with bortezomib.
    Idica A; Kaneku H; Everly MJ; Trivedi HL; Feroz A; Vanikar AV; Shankar V; Trivedi VB; Modi PR; Khemchandani SI; Dave SD; Terasaki PI
    Clin Transpl; 2008; ():229-39. PubMed ID: 19708459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute rejection in a highly sensitized lung transplant recipient with pre-formed donor-directed anti-HLA class II antibodies: role of bortezomib therapy.
    Stuckey LJ; Kamoun M; Wadhwa A; Samaniego M; Bartos C; Berry J; Mahidhara R; Chang AC; Chan KM
    Clin Transpl; 2009; ():471-4. PubMed ID: 20524317
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
    Hamawi K; Heilman RL; Mazur MJ; Chakkera HA; Mulligan DC; Moss AA; Mekeel KL; Reddy KS
    Clin Transpl; 2009; ():407-14. PubMed ID: 20524306
    [No Abstract]   [Full Text] [Related]  

  • 15. Abrogation of anti-HLA antibodies via proteasome inhibition.
    Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
    Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.
    Govil A; Walsh RC; Tevar A; Alloway R; Roy-Chaudhury P; Mogilishetty G; Wall GE; Brailey P; Girnita A; Woodle ES
    Clin Transpl; 2009; ():443-53. PubMed ID: 20524313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib for acute humoral rejection in two repeat transplant recipients.
    Hardinger KL; Alford K; Murillo D
    Clin Transpl; 2009; ():479-83. PubMed ID: 20524319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?
    Lee I; Constantinescu S; Gillespie A; Swami A; Birkenbach M; Leech S; Silva P; Karachristos A; Daller JA; Sifontis NM
    Clin Transpl; 2009; ():425-9. PubMed ID: 20524309
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation.
    Flechner SM; Fatica R; Askar M; Stephany BR; Poggio E; Koo A; Banning S; Chiesa-Vottero A; Srinivas T
    Transplantation; 2010 Dec; 90(12):1486-92. PubMed ID: 21042239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants.
    Weston M; Rolfe M; Haddad T; Lopez-Cepero M
    Clin Transpl; 2009; ():393-9. PubMed ID: 20524304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.